References

Impact of HIV-1 resistance-associated mutations on susceptibility to doravirine: analysis of real-world clinical isolates

10.1128/aac.01216-21 · 2021 · External reference

Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry

10.1016/j.ijantimicag.2023.106737 · 2023 · External reference

Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1 from a randomized trial

10.1097/qad.0000000000004367 · 2026 · External reference

Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV

10.1097/qad.0000000000003513 · 2023 · External reference

HIV treatment with dolutegravir and doravirine: rationale for selection and clinical outcomes in a highly treatment experienced population

10.1177/09564624221116533 · 2022 · External reference

PRESTIGIO RING: “A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ritonavir plus raltegravir”

2023 · External reference

Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors

10.1136/bmjopen-2023-080606 · 2024 · External reference

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens

10.1093/jac/dkae481 · 2025 · External reference

Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry

10.1093/jac/dkaf415 · 2025 · External reference

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure

10.1093/jac/dkad184 · 2023 · External reference